Navigation Links
SEC in Biological Technology

Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock

MONTVALE, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that it has entered into agreements with the current holders of its Series B Preferred Stock, $0.01 par value per share, under which $2,875,000 in accrued dividend obligations r...

EESTECH Inc - Release From SEC Filing

LOS ANGELES, Feb. 18 /PRNewswire-FirstCall/ -- The Board of Directors wishes to confirm to Stockholders that at its meeting on February 4, 2009 it resolved to file a Form 15 with effect from February 17, 2009. This initiative does not require the approval of stockholders but in the interests of k...

Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action

BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT) (the "Company" or "NWBT") announced today settlement of a putative securities class action lawsuit, In re Northwest Biotherapeutics, Inc. Securities Litigation , No. C-...

Former Telomolecular CEO Clarifies SEC Settlement

Former Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD. (PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, was formed in 2005 to develop and license new nanot...

Coherent, Inc. Announces Termination of SEC Informal Inquiry

SANTA CLARA, Calif., July 10 /PRNewswire-FirstCall/ -- Coherent, Inc. (Nasdaq: COHR ), today announced that the Securities and Exchange Commission has formally notified the Company that its investigation of Coherent's historical stock option granting practices has been terminated and that it ...

Immucor Settles SEC Investigation

Court Approves Class Action Settlement NORCROSS, Ga., Sept. 28 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD ), the global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that the Securities and Exchange Comm...

Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs

WALTHAM, Mass., Aug. 20 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO ) announced today that certain executive officers, including Marijn E. Dekkers, president and chief executive officer, are adopting stock- trading programs under Securities and Exchange Commission (SEC)...

Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC

AURORA, Ontario, March 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") announced that its registration statement on Form 20-F has been declared effective by the U.S. Securities and Exchange Commission ("SEC"). Accordingly, Helix's common shares are now registered with the SEC pursu...

NeoGenomics Files Annual Report on Form 10-KSB with the SEC

Also Announces Change to Unaudited Financial Results Released March 18, 2008 FT. MYERS, Fla., April 15 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it had filed with the Securities and Exchange Commission its annua...

National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC

MOUNTAINSIDE, N.J., Dec. 17 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (Other OTC: NHGI) today announced that its company information, financial information, quotations and press releases are posted on the OTCIQ, a service of the Pink Sheets. OTCIQ is a secure, web-based port...

VaxGen Files Last Outstanding Periodic Report With SEC

Plans to Initiate Process to Re-list Common Shares SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed its Form 10-Q for the quarter ended June 30, 2007, thereby bringing the company current on its financia...

Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters

Washington, D.C. A full house packed the Securities and Exchange Commission headquarters on Wednesday for a public forum to discuss the most onerous section of The Sarbanes-Oxley Act of 2002 (or Sarbanes-Oxley), Section 404. The event was a roundtable of public companies, auditors, investor...

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

... Matters" in the Company's Form 8-K filed with the sec on April 30, 2009; (16) the possibility that the C...er ended June 30, 2008, Form 12b-25 filed with the sec on November 13, 2008, Form 12b-25 filed with the sec on February 2, 2009, Form 12b-25 filed with the...

Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product

...ition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's sec filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company unde...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...pany has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the sec are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any...

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

...pies of the prospectus supplements may be obtained by visiting EDGAR on the sec website at www.sec.gov . This communication shall not constitute ...al Report on Form 10-K for the year ended December 31, 2008, filed with the sec under the heading "Risk Factors" for a more detailed description of such fa...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...ut are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the sec on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions ...

China Sky One Medical, Inc. Appoints New Independent Director

...e Audit Committee, Compensation Committee and Finance Committee of the Board of Directors, and as "audit committee financial expert" as defined by the sec rules adopted pursuant to the Sarbanes-Oxley Act of 2002. Mr. Wei Lee has over 15 years of experience in financial services and government rela...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...on in our annual report for the year ended December 31, 2008 filed with the sec on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the sec on Form 10-Q. Given these uncertainties, assumptions and risk factors, in...

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

...essful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended June 30, 2009, which will be filed with the sec on or about August 7, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of ...

Micromet Closes $80.5 Million Public Offering of Common Stock

...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

...ery and development collaborations on current terms. These and other risks and uncertainties are described more fully in Senomyx's most recently filed sec documents, including its Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q under the headings "Risks Related to Our Busines...

Oncothyreon appoints Diana Hausman as Vice President of Clinical Development

...in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the sec and/or Canadian regulatory authorities. Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can gi...

Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

...on in our annual report for the year ended December 31, 2008 filed with the sec on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the sec on Form 10-Q. Given these uncertainties, assumptions and risk factors, re...

SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS

...not adequately protect its proprietary technologies. These and other risks and uncertainties are described more fully in Senomyx's most recently filed sec documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risks Related to Our Business" and "Risks ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

...in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the sec and/or Canadian regulatory authorities. Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can gi...

CuraGen Reports Second Quarter 2009 Financial Results

...liminary joint proxy statement/prospectus with the sec on June 26, 2009. This joint proxy statement/prosp...her documents filed by Celldex or CuraGen with the sec may be obtained free of charge at the SEC's websit...obtain free copies of the documents filed with the sec (i) by contacting CuraGen Corporation, Attn: VP &a...

TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction

...tus and Raptor's and TorreyPines' filings with the sec can also be obtained, without charge, by directing...ormation filed by Raptor and/or TorreyPines at the sec public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the sec at 1-800-SEC-0330 for further information on the p...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

...lity to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' sec filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Current Report on Form 8-K filed on June 4, 2009. All forward-l...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...lity to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' sec filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Current Report on Form 8-K filed on June 4, 2009. All forward-l...

Micromet Announces Pricing of Public Offering of Common Stock

...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...

Cornerstone Therapeutics Announces Closing of Chiesi Transaction

...connection with the transaction with Chiesi, Cornerstone has filed with the sec a preliminary proxy statement and other documents regarding proposed amendm...tatement (when available) and other documents filed by Cornerstone with the sec at the SEC's website at www.sec.gov or from Cornerstone's website at ...

Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System

...iscussed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's other recent sec filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this pr...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

...any or by persons acting on its behalf and in conjunction with its periodic sec filings. In addition, please refer to the cautionary statements and risk fa...te that its Form 10-Q for the quarter ended June 30, 2009 is filed with the sec could potentially result in adjustments to reported results. The company un...

U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare International

...nce finalized, will be filed by HeartWare with the sec and mailed by HeartWare to its stockholders. Inves...pectus and other relevant documents filed with the sec because they contain important information. Securi...documents filed by Thoratec and HeartWare with the sec at the SEC's web site at http://www.sec.gov. The ...

Micromet Announces Public Offering of Common Stock

...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...

Sanofi-aventis Announces Second Quarter 2009 Results

...lternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in san...

BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009

...erformances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the sec and located at www.shareholder.com/biocryst/edgar.cfm . BCRXW ...
Other Tags
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
(Date:7/30/2014)... her eggs until they hatched 4.5 years later, according ... open-access journal PLOS ONE by Bruce Robison ... Octopuses typically have a single reproductive period during their ... their fertilized eggs until they hatch. Shallow-water octopuses typically ... but little is known about the brooding of deep-sea ...
(Date:7/30/2014)... The American Chemical Society (ACS) announced today that David ... ACS Biomaterials Science & Engineering as editor-in-chief. ... 2015, the new journal will feature high-quality research in ... engineered or naturally derived materials that interact with living ... as it reflects the tremendous growth in the field ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
(Date:7/30/2014)... 2014 Daily Gossip mentions that the "Panic ... effective way to stop anxiety and eliminate all associated symptoms. ... no less than 150,000 people in getting their lives back. ... complex anxiety treatment system that will teach sufferers different techniques ... is very simple to access, as it is available in ...
(Date:7/30/2014)... Within weeks freshman will begin to pour onto ... this will be a time of growth and the start to ... it may not be as easy as it looks. Some ... their major at least once and many will switch two or ... costs are exacerbated when switching in the later years of college. ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... Throughout the month of August, Restore Dental will ... Using a new technological tool called The Vue, the ... its early stages. , Oral cancer can include cancers ... other areas in and around the mouth. According to ... (SEER) program, 30 percent of oral cancers originate in ...
(Date:7/30/2014)... Ticket Down is a reputable source for ... friendly exhibition match at the Red Bull Arena in ... that was left standing as the best team in the ... largest football competition and even embarrassed the host nation Brazilian ... Germany was led by seven players that called Bayern Munich ...
Breaking Medicine News(10 mins):Health News:Panic Away Review Reveals How to Stop Anxiety 2Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3
Other Contents